A retrospective study of hepatitis B mother‐to‐child transmission prevention and postvaccination serological test results of infants at risk of perinatal transmission in two counties of middle China
Authors:
- 13 March 2017
- journal article
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 24 (8) , 687-695
Abstract
Summary: Approximately, 240 million people have chronic hepatitis B worldwide, with mother‐to‐child‐transmission (MTCT) accounting for most cases. Therefore, Henan Province, China launched a public health programme to preventMTCT. To determine the efficacy of this health programme, a survey was carried out in Huixian and Xinan counties, which are located in northern and western Henan. All infants born in these two counties between January 1, 2013 and March 31, 2014 to a mother positive for hepatitis B surface antigen (HBsAg) were surveyed. In total, there were 438 mother‐infant pairs. A blood sample was collected from all mothers and infants and the following Hepatitis B virus (HBV) markers, antibodies, and antigens were measured:HBsAg, anti‐HBs, anti‐HBc,HBeAg, anti‐HBe, andHBV‐DNA. All mothers and 5.3% (23/438) of the infants wereHBsAg positive. All infants received three doses of the hepatitis B vaccine (HepB) and the postvaccination serological test (PVST) showed that the appropriate interval forPVSTmay be 1‐8 months after the final HepB dose. Multivariable analysis showed that infants without a timely first and second dose of the HepB, with anHBeAg‐positive mother and mothers who had not received hepatitis B immune globulin during pregnancy were implicated inMTCT. The stratified analysis using maternalHBeAg as a marker showed that maternalHBeAg may be a strong risk factor forMTCT. To preventMTCTin middle China, several courses of action are recommended. The first is to optimize the screening method for the mother to allowHBeAg andHBsAg‐positive mothers to receive medical treatment during pregnancy and a timely birth dose of the vaccine to all infants. Second, all infants with anHBsAg‐positive mother should be tested for anti‐HBs andHBsAg at 7‐14 months old and any anti‐HBs‐nonresponse infants should receive an additional three dosesof the vaccine.Keywords
Funding Information
- Medical science and technology research projects of Henan, China (201302024)
This publication has 21 references indexed in Scilit:
- Effectiveness of prevention of mother-to-child transmission practice in three provinces of Southern ChinaHuman Vaccines & Immunotherapeutics, 2015
- Factors Associated with Mother-to-child Transmission of Hepatitis B Virus Despite ImmunoprophylaxisInternal Medicine, 2015
- Immunization interventions to interrupt hepatitis B virus mother-to-child transmission: a meta-analysis of randomized controlled trialsBMC Pediatrics, 2014
- Economic Evaluation on Hepatitis B Vaccination Strategies for Preventing Mother-To-Child Transmission in ChinaValue in Health, 2014
- Seroprotection after recombinant hepatitis B vaccination among newborn infants: A reviewVaccine, 2013
- Chronic HBV infection among pregnant women and their infants in Shenyang, ChinaVirology Journal, 2013
- An Algorithm for Risk Assessment and Intervention of Mother to Child Transmission of Hepatitis B VirusClinical Gastroenterology and Hepatology, 2012
- Virologic factors associated with failure to passive–active immunoprophylaxis in infants born to HBsAg‐positive mothersJournal of Viral Hepatitis, 2011
- Increased risk of developing chronic HBV infection in infants born to chronically HBV infected mothers as a result of delayed second dose of hepatitis B vaccinationVaccine, 2009
- Hepatitis B mother-to-child transmissionExpert Review of Anti-infective Therapy, 2004